8-K/AEarnings & Results

BRISTOL MYERS SQUIBB CO 8-K/A Report, Financial Results (Aug 27, 2007)

Filed August 27, 2007For Securities:BMYCELG-RIBMYMP

Summary

This 8-K/A filing from Bristol-Myers Squibb Company (BMY) is an amendment to a previous filing, primarily addressing a technical error in the calculation of demand changes for certain key products during the first quarter of 2007. The amendment provides corrected demand percentage changes on a constant U.S. dollar basis for March 2007 versus March 2006 across the International Pharmaceuticals, Nutritionals, and Other Health Care segments. The most significant adjustments relate to substantial downward revisions in estimated patient demand for PRAVACHOL, TAXOL®, and VIDEX/VIDEX EC. Conversely, ABILIFY*, BARACLUDE, DAFALGAN, EFFERALGAN, ORENCIA, PERFALGAN, REYATAZ, and SUSTIVA Franchise showed improved demand growth in the corrected figures. Investors should note these changes as they could impact future revenue projections and the perceived performance of these specific product lines. The filing also references previous adjustments related to the at-risk launch of generic clopidogrel bisulfate impacting PLAVIX volumes.

Key Highlights

  • 1Amendment to a previous 8-K filing detailing corrected financial information.
  • 2Identified a technical error in the calculation of patient demand changes for key products (March 2007 vs. March 2006).
  • 3Significant downward revision in estimated demand for PRAVACHOL from -1% to -73%.
  • 4Substantial downward revision in estimated demand for TAXOL® (paclitaxel) from -5% to -24%.
  • 5Notable downward revision in estimated demand for VIDEX/VIDEX EC from 11% to -2%.
  • 6Upward revisions in estimated demand growth for ABILIFY* (total revenue) from 5% to 33% and REYATAZ from 16% to 24%.
  • 7The filing also references prior disclosures regarding the impact of generic clopidogrel bisulfate on PLAVIX prescription volumes.

Frequently Asked Questions

The primary purpose of this Form 8-K/A (Amendment No. 3) is to correct a technical error in the calculation of estimated patient demand changes for certain key Bristol-Myers Squibb products, specifically for the period of March 2007 compared to March 2006, as previously reported in supplemental information.

The most significant downward revisions in estimated patient demand were for PRAVACHOL (from -1% to -73%), TAXOL® (from -5% to -24%), and VIDEX/VIDEX EC (from 11% to -2%). Conversely, ABILIFY* (total revenue) saw a substantial upward revision in demand growth (from 5% to 33%), and REYATAZ also showed improved demand growth (from 16% to 24%).

These revised demand figures are important for investors as they provide a more accurate picture of product performance and market reception. Significant decreases in demand for products like PRAVACHOL and TAXOL® could signal potential revenue challenges for those specific drugs, while improvements in demand for ABILIFY* and REYATAZ may indicate positive future revenue trends for those products. Investors should consider these corrected figures when evaluating the company's overall financial health and future prospects.

While this filing does not directly amend information about the PLAVIX generic issue, it references previous filings (July 26, 2006) where the company adjusted its estimates related to the adverse effect of the at-risk launch of generic clopidogrel bisulfate due to IMS Health's overstatement of PLAVIX volumes. This current filing focuses on a separate error in demand calculation for other products.